NASDAQ:EYEN - Eyenovia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.82 +0.15 (+3.21 %) (As of 02/22/2019 11:49 AM ET)Previous Close$4.67Today's Range$4.82 - $4.8252-Week Range$2.40 - $10.20Volume100 shsAverage Volume661,058 shsMarket Capitalization$56.78 millionP/E Ratio-2.20Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York. Receive EYEN News and Ratings via Email Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN Previous Symbol CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone917-289-1117Debt Debt-to-Equity RatioN/A Current Ratio12.41 Quick Ratio12.41Price-To-Earnings Trailing P/E Ratio-2.20 Forward P/E Ratio-2.94 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book9.45Profitability EPS (Most Recent Fiscal Year)($2.19) Net Income$-5,120,000.00 Net MarginsN/A Return on Equity-70.37% Return on Assets-66.24%Miscellaneous EmployeesN/A Outstanding Shares11,780,000Market Cap$56.78 million Next Earnings Date4/1/2019 (Estimated) OptionableNot Optionable Eyenovia (NASDAQ:EYEN) Frequently Asked Questions What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." How were Eyenovia's earnings last quarter? Eyenovia Inc (NASDAQ:EYEN) issued its earnings results on Tuesday, August, 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.09. View Eyenovia's Earnings History. When is Eyenovia's next earnings date? Eyenovia is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Eyenovia. What price target have analysts set for EYEN? 1 brokers have issued 12-month target prices for Eyenovia's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Eyenovia's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 192.9% from the stock's current price. View Analyst Price Targets for Eyenovia. What is the consensus analysts' recommendation for Eyenovia? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia. What are Wall Street analysts saying about Eyenovia stock? Here are some recent quotes from research analysts about Eyenovia stock: 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (2/20/2019) 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $240M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate. Probabilities of success assigned are 80%, 75%, 55% and 45% for MicroPine, respectively." (2/14/2019) Has Eyenovia been receiving favorable news coverage? Media headlines about EYEN stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyenovia earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days. Who are some of Eyenovia's key competitors? Some companies that are related to Eyenovia include resTORbio (TORC), Paratek Pharmaceuticals (PRTK), LifeVantage (LFVN), Calithera Biosciences (CALA), Avid Bioservices (CDMO), Strongbridge Biopharma (SBBP), Dova Pharmaceuticals (DOVA), Athersys (ATHX), Cerecor (CERC), Tocagen (TOCA), Affimed (AFMD), Aratana Therapeutics (PETX), Arbutus Biopharma (ABUS), MEI Pharma (MEIP) and Xeris Pharmaceuticals (XERS). What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Centene (CNC), Fate Therapeutics (FATE), ImmunoGen (IMGN), Verastem (VSTM), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE), Ocular Therapeutix (OCUL), Corbus Pharmaceuticals (CRBP), Madrigal Pharmaceuticals (MDGL) and Cara Therapeutics (CARA). Who are Eyenovia's key executives? Eyenovia's management team includes the folowing people: Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)Mr. Luke Clauson, VP of R&D (Age 40)Mr. John P. Gandolfo, CFO & Sec. (Age 58)Mr. Michael M. Rowe, VP of Marketing When did Eyenovia IPO? (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO. Who are Eyenovia's major shareholders? Eyenovia's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Uniplan Investment Counsel Inc. (2.76%) and Bank of New York Mellon Corp (0.11%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Fredric N Eshelman, John P Gandolfo, Michael M Rowe and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia. Which major investors are selling Eyenovia stock? EYEN stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc.. View Insider Buying and Selling for Eyenovia. Which major investors are buying Eyenovia stock? EYEN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Fredric N Eshelman, John P Gandolfo, Michael M Rowe and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia. How do I buy shares of Eyenovia? Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $4.78. How big of a company is Eyenovia? Eyenovia has a market capitalization of $56.31 million. The company earns $-5,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. What is Eyenovia's official website? The official website for Eyenovia is http://www.eyenoviabio.com. How can I contact Eyenovia? Eyenovia's mailing address is 501 Fifth Avenue Suite 1404, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected] MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 66 (Vote Outperform)Underperform Votes: 90 (Vote Underperform)Total Votes: 156MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index?